Eva
Poveda López
Publications by the researcher in collaboration with Eva Poveda López (23)
2019
-
Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain
Open Forum Infectious Diseases, Vol. 6, Núm. 2
-
HTLV testing of solid organ transplant donors
Clinical Transplantation
-
HTLV-1 infection in solid organ transplant donors and recipients in Spain
BMC Infectious Diseases, Vol. 19, Núm. 1
2017
-
Human T-lymphotropic virus type 1 infection and disease in Spain
AIDS, Vol. 31, Núm. 12, pp. 1653-1663
2015
-
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5
-
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5
2013
-
Hepatitis B in HIV-infected patients
Clinics in Liver Disease, Vol. 17, Núm. 3, pp. 489-501
-
Hepatitis C therapy with HCV NS5B polymerase inhibitors
Expert Opinion on Pharmacotherapy, Vol. 14, Núm. 9, pp. 1161-1170
-
Hepatitis C therapy: Highlights from the 2012 annual meeting of the european association for the study of the liver
Clinical Infectious Diseases, Vol. 56, Núm. 4, pp. 560-566
-
Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B
AIDS, Vol. 27, Núm. 14, pp. 2219-2224
-
Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy
Journal of Clinical Virology, Vol. 58, Núm. 2, pp. 391-395
-
Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain
Liver International, Vol. 33, Núm. 9, pp. 1357-1362
-
The changing face of hepatitis C in the new era of direct-acting antivirals
Antiviral Research
-
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C
Antiviral Therapy, Vol. 18, Núm. 8, pp. 1033-1035
2012
-
Pharmacogenetics of hepatitis C
Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 3, pp. 523-529
-
Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain
Antiviral Therapy, Vol. 17, Núm. 3, pp. 571-575
-
Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor
Antiviral Therapy, Vol. 17, Núm. 5, pp. 921-926
-
Treatment failure with new hepatitis C drugs
Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 3, pp. 313-323
2011
-
Directly acting antivirals against hepatitis C virus
Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 8, pp. 1673-1686
2009
-
Raltegravir and etravirine are active against HIV Type 1 group O
AIDS Research and Human Retroviruses, Vol. 25, Núm. 2, pp. 225-227